MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) today announced that clinical study data for STEDESA™ (eslicarbazepine acetate [ESL]) were presented during a scientific poster session at the 2010 annual meeting of the American Epilepsy Society (AES) in San Antonio, Texas. Three posters were presented during the scientific poster sessions. The first was based on data from a Phase I study of cerebrospinal fluid (CSF) and plasma pharmacokinetics of ESL and oxcarbazepine (OXC). Two other posters included safety and efficacy derived from the pooled results of two, placebo-controlled Phase III studies of ESL in which patients had a history of at least four partial-onset seizures per month despite treatment with one to three concomitant antiepileptic drugs (AEDs) and who were randomized to ESL 400 mg, 800 mg, 1200 mg or placebo.
